Premium
Heat shock protein 90 inhibition and multi‐target approach to maximize cardioprotection in ischaemic injury
Author(s) -
Der Sarkissian Shant,
Aceros Henry,
Williams PierreMarc,
Scalabrini Catherine,
Borie Mélanie,
Noiseux Nicolas
Publication year - 2020
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.15075
Subject(s) - cardioprotection , heat shock protein , medicine , disease , shock (circulatory) , ischaemic heart disease , bioinformatics , neuroscience , pharmacology , ischemia , biology , cardiology , biochemistry , gene
Despite several advances in medicine, ischaemic heart disease remains a major cause of morbidity and mortality. The unravelling of molecular mechanisms underlying disease pathophysiology has revealed targets for pharmacological interventions. However, transfer of these pharmcological possibilities to clinical use has been disappointing. Considering the complexity of ischaemic disease at the cellular and molecular levels, an equally multifaceted treatment approach may be envisioned. The pharmacological principle of ‘one target, one key’ may fall short in such contexts, and optimal treatment may involve one or many agents directed against complementary targets. Here, we introduce a ‘multi‐target approach to cardioprotection’ and propose heat shock protein 90 (HSP90) as a target of interest. We report on a member of a distinct class of HSP90 inhibitor possessing pleiotropic activity, which we found to exhibit potent infarct‐sparing effects.